CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 138 target
Drug / intervention
AK109 +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04982276
NCT04982276Phase 2RecruitingUpdate OverdueUpdated 7mo ago · Completion was 6mo ago
Enrollment Stalled
Long Recruiting
Update Overdue
CompareCT.gov

A Multicentre, Phase Ib/II Clinical Study of AK109 and AK104 With or Without Chemotherapy in Second-line Treatment of Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Akeso·interventional·Posted Jul 29, 2021·Updated Nov 19, 2025

In Brief

A Phase 2 clinical trial evaluating AK109, paclitaxel, and 1 other intervention for Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma. Currently recruiting, targeting 138 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

This is a multicentre, Phase Ib/II Clinical Study of AK109 and AK104 With or Without Chemotherapy in Second-line Treatment of Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma .

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
CountriesChina
Collaborators--

Timeline

Phase 2Recruiting
202220232024202520262027
First PostedJul 29, 2021
Enrollment StartAug 23, 2021
Primary CompletionDec 30, 2025
Study CompletionJan 31, 2027
TodayJul 1, 2026
Enrollment to primary: 4.4 yearsPosted 4.9 years ago

Interventions

AK109biological

Subjects will receive AK109 by intravenous administration.

paclitaxeldrug

Subjects will receive AK109 in combination with paclitaxel.

paclitaxeldrug

Subjects will receive AK104 and AK109 in combination with paclitaxel.

AK104biological

Subjects will receive AK104 by intravenous administration.